News and Topics
Featured News
Public engagement is key to building momentum for longevity science, and you can make a real difference. Our nonprofit team works hard to bring you the latest news in the field. Please consider making a donation to support our work. Thank You.
The report, titled “Pathways to Longevity”, introduces several important longevity concepts to the general reader and is another sign that the
In a preprint published in arXiv, researchers from Altos Labs have described a machine learning algorithm that performs end-to-end prediction of
Scientists have demonstrated how cancer cells influence neighboring cells to create a favorable niche for the tumor to grow. Understanding this
A recent study compared premenopausal, perimenopausal, and postmenopausal women’s cardiovascular health. Perimenopausal women had about twice the odds of having a
Scientists have uncovered an unexpected function of the tau protein, which is mostly known for its role in Alzheimer’s and related
Researchers have discovered the role of cellular senescence in the interaction between omega-3 polyunsaturated fatty acids (PUFAs) and chronic kidney disease
Scientists have found that the levels of phosphatidylcholine, the most abundant lipid in mitochondrial membranes, decline with age, driving mitochondrial aging
Researchers have outlined a key receptor and protein involved in the formation of cataracts, paving the way for potential treatments targeting
In Aging Cell, researchers have described the differences between primary and secondary senescent cells, comparing radiation-induced senescence to senescence induced by
Beijing, China — In response to the growing healthcare demands of a rapidly ageing population, China has launched its first national
Scientists have devised a CRISPR-based tool that can kill cells carrying a specific strand of RNA. The tested targets include cancerous
We have spoken with Reason from Repair Biotechnologies about his company’s lead candidate, REP-0004, a drug targeting the liver to reduce
Most cardiovascular trials focus on lowering LDL cholesterol or reducing inflammation to slow disease progression. UDP-003 targets the root cause: toxic
Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and remove